Clinical trial
Weight Loss Intervention With Semaglutide in Patients With Estrogen Receptor-positive Breast Cancer (WISPER): A Phase II, Randomized, Open-label, Single-center, Delayed-start Feasibility Trial of Glucagon-like Peptide-1 Receptor Agonist Therapy During Adjuvant Endocrine Therapy.
NCT07909889 is registered in ClinicalTrials.gov with Aarhus University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Weight Loss Intervention With Semaglutide in Patients With Estrogen Receptor-positive Breast Cancer (WISPER): A Phase II, Randomized, Open-label, Single-center, Delayed-start Feasibility Trial of Glucagon-like Peptide-1 Receptor Agonist Therapy During Adjuvant Endocrine Therapy.
- Lead sponsor
- Aarhus University Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- March 31, 2027
- Completion date
- September 30, 2029
- Enrollment
- 32 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer (early breast cancer), obesity
Arms
As registered; 2 arms.
-
Immediate-start semaglutide
Participants receive semaglutide once weekly for 26 weeks starting at randomization, followed by 26 weeks of post-treatment observation. Usual adjuvant endocrine therapy, routine oncology follow-up and standardized written guidance on diet and physical activity continue throughout participation.
-
Delayed-start semaglutide
Participants receive standard care alone for the first 26 weeks after randomization, then semaglutide once weekly for 26 weeks, followed by 26 weeks of post-treatment observation. Standard care comprises usual adjuvant endocrine therapy, routine oncology follow-up and standardized written guidance on diet and physical activity. Total follow-up is 78 weeks from randomization.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Completion of the 26-week semaglutide treatment phase meeting all composite feasibility criteria
Percentage of participants who complete the assigned 26-week treatment phase while meeting all three criteria: no permanent discontinuation of prescribed adjuvant endocrine therapy; no permanent discontinuation of semaglutide; and administration of at least 21 of 26 planned weekly semaglutide injections. Endocrine therapy continuation is assessed from prescription records and self-reported intake; semaglutide adherence is assessed from electronic dosing diaries with pen reconciliation. The proportion will be reported with a 95% confidence interval.
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Semaglutide
- US 11318191; expires February 17, 2041; assignee Novo Nordisk A S
- US 11478533; expires May 13, 2040; assignee Novo Nordisk A S
- US 11833248; expires February 1, 2039; assignee Novo Nordisk A S
- US 12396953; expires February 1, 2039; assignee Novo Nordisk A S
- US 12029779; expires October 10, 2038; assignee Novo Nordisk A S
- +36 more patents
Lead sponsor's other trials
Aarhus University Hospital, most recent start first.
+292 more trials See the organization page
Similar trials
Same condition (Weight Loss) and phase, most recent start first.
+103 more trials See the condition page